ID   UCD115
AC   CVCL_ZV45
DR   Wikidata; Q98133835
RX   PubMed=32576280;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Characteristics: Established from a patient-derived xenograft.
CC   Doubling time: 65.4 hours, 67.7 hours (Note=With 17-beta-estradiol) (PubMed=32576280).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys305fs*47 (c.892_911dupGAGCTGCCCCCAGGGAGCAC); Zygosity=Unspecified (PubMed=32576280).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 10-04-25; Version: 7
//
RX   PubMed=32576280; DOI=10.1186/s13058-020-01300-y; PMCID=PMC7310532;
RA   Finlay-Schultz J., Jacobsen B.M., Riley D., Paul K.V., Turner S.,
RA   Ferreira-Gonzalez A., Harrell J.C., Kabos P., Sartorius C.A.;
RT   "New generation breast cancer cell lines developed from
RT   patient-derived xenografts.";
RL   Breast Cancer Res. 22:68.1-68.12(2020).
//